Options
Deleterious effects of VEGFR2 and RET inhibition in a preclinical model of Parkinson’s disease
6-OHDA
Neurotrophic factors
Parkinson’s disease
Preclinical model
RET
Vandetanib
VEGFR2
caspase 3
glial fibrillary acid...
mitogen activated pro...
mitogen activated pro...
oxidopamine
protein kinase B
protein Ret
sodium chloride
tyrosine 3 monooxygen...
v 9402
vandetanib
vasculotropin recepto...
KDR protein, human
N-(4-bromo-2-fluoroph...
piperidine derivative...
protein Ret
quinazoline derivativ...
Ret protein, rat
vasculotropin recepto...
animal cell
animal experiment
animal model
animal tissue
Article
biochemistry
controlled study
drug effect
enzyme inhibition
experimental behavior...
histology
immunohistochemistry
male
nerve cell
neuroprotection
nigroneostriatal syst...
nonhuman
Parkinson disease
protein expression
protein function
rat
signal transduction
substantia nigra
Western blotting
animal
antagonists and inhib...
chemically induced
metabolism
parkinsonism
pathology
Sprague Dawley rat
treatment outcome
Animals
Male
Parkinsonian Disorder...
Piperidines
Proto-Oncogene Protei...
Quinazolines
Rats
Rats, Sprague-Dawley
Treatment Outcome
Vascular Endothelial ...